CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations

Michael A. Province, Matthew P. Goetz, Hiltrud Brauch, David A. Flockhart, Joan M. Hebert, Ryan Whaley, Vera J. Suman, Werner Schroth, Stefan Winter, Hitoshi Zembutsu, Taisei Mushiroda, William G. Newman, M-t M Lee, Christine B. Ambrosone, Matthias W. Beckmann, J-y Choi, A-s Dieudonné, Peter A. Fasching, Roberta Ferraldeschi, Li Gong, Elisabeth Haschke‐Becher, Anthony Howell, Lee B. Jordan, Ute Hamann, Kazuma Kiyotani, Peter Krippl, Diether Lambrechts, Ayşe Latif, Uwe Langsenlehner, Wendy Lorizio, Patrick Neven, Anne Nguyen, Byeong‐Woo Park, Colin A. Purdie, Philip Quinlan, Wilfried Renner, Marcus Schmidt, Matthias Schwab, J-g Shin, Julia Stingl, Pia Wegman, Sten Wingren, Alan H.b. Wu, Elad Ziv, Gary Zirpoli, Alastair M. Thompson, V. Craig Jordan, Yoshihiko Nakamura, Russ B. Altman, Matthew M. Ames, Richard M. Weinshilboum, Michel Eichelbaum, James N. Ingle, Teri E. KleinClinical 2013 · DOI

Abstract

The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor-positive breast cancer, receiving 20 mg/day tamoxifen for 5 years, criterion 1); CYP2D6 poor metabolizer status was associated with poorer invasive disease-free survival (IDFS: hazard ratio = 1.25; 95% confidence interval = 1.06, 1.47; P = 0.009). However, CYP2D6 status was not statistically significant when tamoxifen duration, menopausal status, and annual follow-up were not specified (criterion 2, n = 2,443; P = 0.25) or when no exclusions were applied (criterion 3, n = 4,935; P = 0.38). Although CYP2D6 is a strong predictor of IDFS using strict inclusion criteria, because the results are not robust to inclusion criteria (these were not defined a priori), prospective studies are necessary to fully establish the value of CYP2D6 genotyping in tamoxifen therapy.
BibTeX
@inproceedings{province2013cyp,
  author = {Michael A. Province and Matthew P. Goetz and Hiltrud Brauch and David A. Flockhart and Joan M. Hebert and Ryan Whaley and Vera J. Suman and Werner Schroth and Stefan Winter and Hitoshi Zembutsu and Taisei Mushiroda and William G. Newman and M-T M Lee and Christine B. Ambrosone and Matthias W. Beckmann and J-Y Choi and A-S Dieudonné and Peter A. Fasching and Roberta Ferraldeschi and Li Gong and Elisabeth Haschke‐Becher and Anthony Howell and Lee B. Jordan and Ute Hamann and Kazuma Kiyotani and Peter Krippl and Diether Lambrechts and Ayşe Latif and Uwe Langsenlehner and Wendy Lorizio and Patrick Neven and Anne Nguyen and Byeong‐Woo Park and Colin A. Purdie and Philip Quinlan and Wilfried Renner and Marcus Schmidt and Matthias Schwab and J-G Shin and Julia Stingl and Pia Wegman and Sten Wingren and Alan H.B. Wu and Elad Ziv and Gary Zirpoli and Alastair M. Thompson and V. Craig Jordan and Yoshihiko Nakamura and Russ B. Altman and Matthew M. Ames and Richard M. Weinshilboum and Michel Eichelbaum and James N. Ingle and Teri E. Klein},
  title = {{CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations}},
  booktitle = {Clinical},
  year = {2013},
  doi = {10.1038/clpt.2013.186},
}

Loading related content...

Figure